Nano-Cap Incannex's Sleep Apnea Candidate Shows Effectiveness And Safety In Mid-Stage Trial

On Wednesday, Incannex Healthcare Inc. (NASDAQ:IXHL) released topline results from its RePOSA Phase 2 clinical trial evaluating IHL-42X, a novel oral drug candidate for obstructive sleep apnea (OSA), a condition affecting over 900 million people worldwide. OSA is a common sleep disorder where…